GlaxoSmithKline announces $300 million equity investment in 23andMe

7:36 AM ET Wed, 25 July 2018

This is an important way to capture important genomic information, says Hal Barron, GlaxoSmithKline chief scientific officer, and Richard Scheller, 23andMe chief scientific officer talking about GSK's investment into the personal genetic company.